PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
作者信息
Calais Jeremie, Czernin Johannes
机构信息
David Geffen School of Medicine at UCLA, Los Angeles, California.
出版信息
J Nucl Med. 2021 Nov;62(11):1489-1491. doi: 10.2967/jnumed.121.263159.
Abstract
摘要
相似文献
1
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.通过PET成像评估的PSMA表达是选择任何PSMA靶向治疗患者所需的生物标志物。
J Nucl Med. 2021 Nov;62(11):1489-1491. doi: 10.2967/jnumed.121.263159.
2
Will GRPR Compete with PSMA as a Target in Prostate Cancer?胃泌素释放肽受体（GRPR）会成为前列腺癌中与前列腺特异性膜抗原（PSMA）竞争的靶点吗？
J Nucl Med. 2017 Dec;58(12):1883-1884. doi: 10.2967/jnumed.117.198192. Epub 2017 Sep 28.
3
Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?推动PSMA靶向诊疗技术走向临床：常识能否占上风？
J Nucl Med. 2017 Aug;58(8):1186-1187. doi: 10.2967/jnumed.117.193516. Epub 2017 May 4.
4
A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.核医学的新视角：拓展前列腺特异性膜抗原（PSMA）靶向成像与治疗的适应症
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1611-1613. doi: 10.1007/s00259-017-3767-4. Epub 2017 Jul 4.
5
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描衍生风险分层工具在高危和极高危前列腺癌中的性能。
JAMA Netw Open. 2021 Dec 1;4(12):e2138550. doi: 10.1001/jamanetworkopen.2021.38550.
6
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.前列腺特异性膜抗原（PSMA）配体用于前列腺癌的诊断和治疗。
Expert Rev Mol Diagn. 2016 Nov;16(11):1177-1188. doi: 10.1080/14737159.2016.1243057. Epub 2016 Oct 14.
7
Current use of PSMA-PET in prostate cancer management.PSMA-PET 在前列腺癌管理中的当前应用。
Nat Rev Urol. 2016 Apr;13(4):226-35. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23.
8
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.转移性前列腺癌中，起始雄激素通路阻断后前列腺特异性膜抗原正电子发射断层扫描示踪剂摄取出现异质性 flares。
Eur Urol Oncol. 2018 May;1(1):78-82. doi: 10.1016/j.euo.2018.03.010. Epub 2018 May 15.
9
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.前列腺特异性膜抗原（PSMA）靶向 PET 成像在前列腺癌中的应用：重要陷阱的最新研究进展。
Semin Nucl Med. 2019 Jul;49(4):255-270. doi: 10.1053/j.semnuclmed.2019.02.006. Epub 2019 Mar 4.
10
Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.前列腺特异性膜抗原PET成像在前列腺癌中的当前应用及未来展望
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub 2018 Mar 8.
引用本文的文献
1
PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making.前列腺特异性膜抗原（PSMA）影像报告和数据系统（PSMA-RADS）2.0：PSMA靶向成像解读与临床决策的修订框架
Abdom Radiol (NY). 2025 Jun 14. doi: 10.1007/s00261-025-05068-7.
2
A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer.转移性去势抵抗性前列腺癌谱系可塑性的复杂系统发育
NPJ Precis Oncol. 2025 Mar 28;9(1):91. doi: 10.1038/s41698-025-00854-4.
3
Joint EANM/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT).EANM/SNMMI 联合实践指南：Lu 标记的 PSMA 靶向放射性配体治疗（Lu-PSMA-RLT）的应用。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29.
4
Special Issue "In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research".特刊“药物研发与药理研究中的体内核分子成像”
Pharmaceuticals (Basel). 2023 Mar 20;16(3):459. doi: 10.3390/ph16030459.
5
Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.新型转移性激素敏感前列腺癌（mHSPC）的 Ac-PSMA-617 放射性配体治疗：初步临床发现。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2210-2218. doi: 10.1007/s00259-023-06165-9. Epub 2023 Mar 3.
6
Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.基于前列腺特异性膜抗原的成像和放射性配体疗法在去势抵抗性前列腺癌中的当前作用。
Front Cell Dev Biol. 2022 Aug 12;10:958180. doi: 10.3389/fcell.2022.958180. eCollection 2022.
7
Radiolabeled PSMA Inhibitors.放射性标记的前列腺特异性膜抗原（PSMA）抑制剂
Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255.
8
The VISION Forward: Recognition and Implication of PSMA-/F-FDG+ mCRPC.《愿景向前：PSMA-/F-FDG+ mCRPC 的识别与意义》。
J Nucl Med. 2022 Jun;63(6):812-815. doi: 10.2967/jnumed.121.263274. Epub 2021 Dec 21.
本文引用的文献
1
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.扫描与否：PSMA放射性配体疗法中不必要的困境
J Nucl Med. 2021 Nov;62(11):1487-1488. doi: 10.2967/jnumed.121.263035. Epub 2021 Aug 26.
2
What's behind Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.Ga-PSMA-11 在原发性前列腺癌 PET 中的摄取背后是什么？对组织病理学参数和免疫组织化学 PSMA 表达模式的调查。
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4042-4053. doi: 10.1007/s00259-021-05501-1. Epub 2021 Aug 13.
3
Nomograms to predict outcomes after Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.Lu-PSMA 治疗转移性去势抵抗性前列腺癌患者预后的列线图：一项国际多中心回顾性研究。
Lancet Oncol. 2021 Aug;22(8):1115-1125. doi: 10.1016/S1470-2045(21)00274-6. Epub 2021 Jul 8.
4
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
5
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.[吕]Lu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）患者：一项随机、开放标签、2 期试验。
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
6
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.前列腺特异性膜抗原的影像学表现与转移性去势抵抗性前列腺癌对 PSMA 靶向β发射放射性核素治疗的反应
Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19.
7
Prognostic implications of dual tracer PET/CT: PSMA ligand and [F]FDG PET/CT in patients undergoing [Lu]PSMA radioligand therapy.双示踪剂 PET/CT 的预后意义：PSMA 配体和 [F]FDG PET/CT 在接受 [Lu]PSMA 放射性配体治疗的患者中的应用。
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2024-2030. doi: 10.1007/s00259-020-05160-8. Epub 2020 Dec 18.
8
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving Lu-PSMA-617 Radioligand Therapy.接受 Lu-PSMA-617 放射性配体治疗的晚期前列腺癌患者中 PSMA 表达与结局分析。
Theranostics. 2020 Jun 19;10(17):7812-7820. doi: 10.7150/thno.47251. eCollection 2020.
9
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.接受[177Lu]-PSMA-617治疗的转移性去势抵抗性前列腺癌男性患者的预后生物标志物
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2322-2327. doi: 10.1007/s00259-020-04723-z. Epub 2020 Mar 5.
10
Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.研究 PSMA 靶向放射性配体治疗的疗效与细胞 PSMA 水平和肿瘤内 PSMA 异质性的关系。
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955. doi: 10.1158/1078-0432.CCR-19-1485. Epub 2020 Jan 13.
Zotero 插件